Skip to content

Phase II study of Docetaxel and CDDP and 5-FU for metastatic esophageal cancer

Phase II study of Docetaxel and CDDP and 5-FU for metastatic esophageal cancer - OGSG 0403

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000000821
Enrollment
45
Registered
2007-09-07
Start date
2004-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients to be registered Esophageal cancer with distant metastasis (Stage IVb or stage IVa with N4)

Interventions

Sponsors

OGSG
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) with measurable lesion 2) esophageal cancer (Squamous cell carcinoma) diagnosed histologically or cytologically 3) without any prior therapy (surgery , chemotherapy or radiation therapy) 4) with distant metastasis 5) age: more than 20 years old and less than 75 ys. Old 6) Performance Status: 0 – 2 7) without any disorder in the important organs 1. WBC: 4,000 <= and <= 12,000/mm3 2. Neutrocyte >= 2,000 /mm3 3. Platelet: >= 10,000 /mm3 4. Hemoglobin: >= 9.0 g/dl 5. Total Bilirubin: <= 1.5 mg/dl 6. GOT, GPT: less than 2.5 times of normal range of each institute 7. serum Creatinin: <= 1.2 mg/dl Or Creatinin Clearance: more than 60 ml/min *Crockcroft-Gault method can be used instead of CC 8. PaO2: >= 70 torr (room air) 8) longer than 3 months of expected survival 9) with written informed consent

Exclusion criteria

Exclusion criteria: 1) severe disorders in The other organs(cardiac disorder, pulmonary fibrosis or interstitial pneumonia, Liver dysfunction) 2) brain metastasis with symptoms 3) edema which needs treatment 4) severe infectious disease 5) with high fever upper than 38 0C 6) with active double cancer 7) women under pregnancy and/or nursing or women who expects pregnancy 8) with a history of severe allergic reaction against medicines 9) uncontrolled cavity fluid in the chest, abdomen or heart 10) doctor's decision not to register to this regimen

Design outcomes

Primary

MeasureTime frame
Response Rate

Secondary

MeasureTime frame
feasibility, survival period, survival time before progression (Time To Progression: TTP)

Countries

Japan

Contacts

Public ContactShigeyuki Tamura/Hirohumi Miki

Kansai Rosai Hospital Dpt. surgery

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026